• Policy
• MFDS prepares a list of pre-requisite data for inspections
• by Lee, Hye-Kyung Feb 7, 2023 05:47am

• Policy
• Further proposals made for reimb of diabetes combos
• by Lee, Tak-Sun Feb 7, 2023 05:47am

• Policy
• Non-face-to-face treatment included as key policy task
• by Kang, Shin-Kook Feb 7, 2023 05:47am

• Company
• SGLT-2 Market ↑3x in 3 years
• by Jung, Sae-Im Feb 7, 2023 05:47am

• Policy
• The price of AbbVie Skyrizi is likely to be adjusted
• by Lee, Tak-Sun Feb 6, 2023 05:51am

• Company
• Does the Xospata dosing cycle limit disappear?
• by Eo, Yun-Ho Feb 6, 2023 05:51am

• Opinion
• [Reporter’s View] Improving NHI-related legislation
• by Lee, Jeong-Hwan Feb 6, 2023 05:51am

• InterView
• SGLT-2 I is a great help in the treatment of heart failure
• by Kim, Jin-Gu Feb 6, 2023 05:51am

• Company
• Mavyret occupies 85% of HCV market...sales fall 36% in 3 yrs
• by Kim, Jin-Gu Feb 6, 2023 05:51am

• Company
• EXKIVITY, PO lung cancer treatment, is released
• by Jung, Sae-Im Feb 3, 2023 08:51am